Recent Developments: FDA Rejection & Patent Setback
FDA Rejection and Stock Collapse: Corcept Therapeutics (NASDAQ: CORT), a biotech focused on cortisol-modulating drugs, faced a major setback at the end of 2025. On Dec. 31, 2025, the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application (NDA) for relacorilant – intended to treat Cushing’s syndrome (hypercortisolism) (www.biospace.com). The FDA found that while one Phase 3 trial (GRACE) met its primary endpoint, a second trial showed relacorilant was “statistically no better than placebo”, and concluded additional evidence of efficacy is needed (www.biospace.com). This surprise rejection sent Corcept’s shares plunging ~50% in one day to ~$34.80 (www.biospace.com), erasing roughly half the company’s market value. Analysts immediately slashed expectations – for example, Truist Securities cut its price target from $135 to $50 following the news (www.biospace.com), reflecting a sharply dimmed outlook for Corcept’s growth.
Class Action Lawsuits: The CRL and resulting stock crash have spurred shareholder litigation. Multiple investor rights firms (Hagens Berman, Portnoy Law, Robbins LLP, etc.) announced investigations or class-action suits alleging Corcept misled investors (www.prnewswire.com) (www.globenewswire.com). The complaint centers on claims that management overstated relacorilant’s prospects – e.g. during 2024–2025, executives touted “powerful support” from relacorilant’s trials for the NDA (ir.corcept.com), despite one pivotal study failing to meet its primary endpoint. In other words, investors allege Corcept painted an overly optimistic picture of relacorilant’s efficacy and approval likelihood. Hagens Berman noted it is probing whether Corcept “may have misled investors about relacorilant's efficacy and commercial prospects” (www.prnewswire.com). These lawsuits are at an early stage; Corcept previously settled a 2019 securities class suit with a $14 million payment (covered by insurance) (www.sec.gov) (www.sec.gov), so the new litigation is a red flag for corporate transparency and could pose financial or reputational risk.
Patent Loss and Generic Threat: In February 2026, Corcept suffered another blow. On Feb. 19, 2026, the U.S. Court of Appeals (Federal Circuit) upheld a 2023 decision in favor of Teva Pharmaceutical, affirming that Teva’s generic version of Korlym (Corcept’s flagship Cushing’s drug) does not infringe Corcept’s patents (news.bloomberglaw.com) (www.sec.gov). This effectively invalidated Corcept’s last legal barrier to generic competition for Korlym. The news sent CORT shares down as much as 28% intraday to multi-year lows (news.bloomberglaw.com). Corcept’s CEO expressed disappointment and noted the disputed patents cover “methods of safely treating [Cushing’s] that physicians rely on every day,” hinting at potential further appeals (www.morningstar.com) (www.morningstar.com). However, unless Corcept finds some other legal remedy, generic mifepristone will erode Korlym sales. Notably, Korlym’s composition-of-matter patent has already expired (www.sec.gov). Corcept’s strategy had been to protect its franchise with method-of-use patents lasting to 2028–2038 (www.sec.gov), and by launching its own authorized generic in 2024 (www.sec.gov) (www.sec.gov). But with the Teva case lost, multiple generics (Teva, and others like Sun and Hikma via prior settlements) are now cleared to enter the market (www.sec.gov). This raises serious concerns about revenue durability, as Korlym (including Corcept’s authorized generic) accounted for essentially all of the company’s $761 million in 2025 sales.
Why this tiny nickel company could be the government's next buy — click to expand
Dividend Policy & Shareholder Returns
No Dividend – Focus on Buybacks: Corcept has never paid a cash dividend and does not plan to in the foreseeable future (www.sec.gov) (www.sec.gov). The company chooses to return capital via share repurchases instead of dividends. In 2025, Corcept aggressively bought back stock – spending $245.9 million on share repurchases (net of option exercises) under its buyback program (www.biospace.com). This amounted to roughly one-third of annual revenue, a significant deployment of cash to reduce the share count and boost shareholder value. The buybacks reflect management’s confidence in the business (or were perhaps an effort to support the stock price). However, given recent events, investors may question if that capital would have been better conserved. With no dividend, the stock’s yield is 0%, so investors are relying entirely on price appreciation for returns (www.sec.gov). Going forward, Corcept’s ability to continue large buybacks may be constrained by the need to fund new trials or offset lost Korlym sales. For now, the company’s shareholder return policy remains weighted toward opportunistic repurchases rather than any income distribution.
Financial Position and Leverage
Strong Cash, No Debt: Corcept entered 2026 with a solid balance sheet. As of Dec. 31, 2025, the company held $532.4 million in cash and marketable investments (www.biospace.com), providing substantial liquidity. Importantly, Corcept carries no significant debt – the balance sheet shows no funded borrowings, only routine liabilities like payables, accrued expenses, and minor lease obligations (www.sec.gov) (www.sec.gov). In fact, Corcept generates interest income (about $24.5 million in 2024) given its large cash reserves and lack of interest-bearing debt (www.sec.gov). This conservative capital structure means leverage is essentially zero, insulating the company from interest rate or refinancing risks. With total liabilities of only $161 million (mostly working capital and tax accruals) against $840 million in assets (www.sec.gov) (www.sec.gov), Corcept’s financial health appears strong on paper. There are no looming debt maturities to worry about. The ample cash stockpile – equivalent to roughly 5 years’ worth of 2025 net income – gives Corcept a buffer to absorb setbacks and fund R&D. It may prove crucial now for financing new clinical trials (if required for relacorilant’s approval) or weathering a revenue drop post-generics. Overall, liquidity and solvency are a bright spot, and interest coverage isn’t a concern (there are effectively no interest expenses to cover). The key question is how management will deploy this cash: for continued buybacks, potential acquisitions, or internal reinvestment to rebuild the growth pipeline.
Start collecting royalty checks before the first national payout.
Step 1
Learn the exact royalty play paying monthly checks
Step 2
Start with as little as $50 — get paid next month
Step 3
Position yourself before Wall Street moves in
Earnings & Cash Flow Coverage
Profitability and Coverage: Despite the recent turmoil, Corcept remained profitable in 2025. Net income was $99.7 million for the year (www.biospace.com), a decline from $141 million in 2024 as expenses rose and revenue growth slowed. Operating cash flow has historically been strong, bolstered by high-margin Korlym sales (the drug is an orphan indication therapy, typically commanding premium pricing). Even after significant share repurchases, Corcept’s year-end cash only fell by ~$70 million year-over-year (www.biospace.com), implying robust underlying cash generation. With no debt obligations, the concept of “coverage” mostly applies to the ability to cover operating needs and any future shareholder returns. By that measure, Corcept’s 2025 free cash flow comfortably covered its reduced net income and buyback outlays, thanks to prior accumulated cash. Looking ahead, however, coverage ratios could deteriorate if Korlym revenue declines sharply and R&D spending ramps up. The company’s profits currently more than cover its minimal fixed charges (e.g. lease payments), but investors should monitor if earnings can “cover” continued buybacks or potential future dividends. Any initiation of a dividend is unlikely near-term given the uncertain outlook and the company’s stated preference for reinvestment and repurchases (www.sec.gov) (www.sec.gov). In summary, Corcept’s coverage of obligations is very strong right now – a function of zero debt and ongoing profitability – but sustaining that will hinge on managing the impact of generics and funding required for relacorilant’s development.
Valuation and Comparables
Current Valuation Metrics: After the roughly 50% stock price crash, Corcept trades at a much lower valuation than just a few months ago, but still not “cheap” given the uncertainties. At ~$35 per share (post-CRL), the trailing P/E ratio is about 42x (using 2025 EPS of $0.82 (www.biospace.com) and the recent price (www.biospace.com)). This elevated multiple reflects the market’s expectation of future growth from Corcept’s pipeline – an expectation now in question. In terms of sales, the stock trades around 5× 2025 revenue (market cap ~$4–4.5 billion vs. $761 million sales) which is a richer price-to-sales than many pharma peers, especially considering the risk to those sales. Even after the decline, Corcept vastly outperformed the broader biotech sector through 2023, so some would argue the valuation still embeds pipeline optimism. Comparables: Pure-play orphan drug companies with a single product and looming generic competition often trade at low earnings multiples due to the “melting ice cube” of revenue. By contrast, Corcept’s valuation has been buoyed by relacorilant’s potential across multiple indications. For instance, competitor Xeris Biopharma (which markets Recorlev® for Cushing’s) is much smaller and unprofitable, so direct P/E comparisons are not meaningful (www.sec.gov). However, Corcept’s enterprise value (~$3.7 billion after net cash) is several times higher than Xeris’ market cap, underscoring Corcept’s dominant share of the Cushing’s market and the market’s higher expectations for its pipeline. Post-CRL, those expectations have reset downward. Sell-side analysts have drastically cut future revenue and profit forecasts – in one stark example, Truist’s revised $50 target implies a modest valuation assuming relacorilant’s Cushing’s indication may be delayed years (www.biospace.com). Until there is clarity on relacorilant’s path forward or success in other trials, Corcept’s valuation could remain in flux, balancing its cash-rich, profitable core business against an uncertain growth trajectory.
Key Risks and Red Flags
Generic Erosion of Korlym: The biggest risk is the imminent generic competition for Korlym. Korlym (mifepristone 300 mg) has been Corcept’s cash cow since 2012, used to treat endogenous Cushing’s syndrome (www.sec.gov). Orphan exclusivity expired in 2019, and now with patents faltering, generics are already here or on the horizon. Teva launched a generic Korlym “at-risk” in Jan 2024 (www.sec.gov) (www.sec.gov), and others (Sun, Hikma) have rights to enter under settlement terms (www.sec.gov). Corcept managed to grow 2024 sales by 40% despite Teva’s entry (ir.corcept.com) (www.sec.gov), partly by introducing its own authorized generic to retain market share (www.sec.gov). But the pricing pressure and share loss are likely to accelerate. Multiple lower-cost generics will force Korlym’s price down and/or siphon volume. This threatens Corcept’s core revenue stream, which could shrink dramatically in the next 1–2 years. Corcept itself has warned that availability of generic mifepristone could materially harm its results (www.sec.gov) (www.sec.gov) – a risk now becoming reality. Investors should be prepared for a possible sharp decline in revenues and margins once generic competition fully materializes.
Regulatory and Pipeline Risks: Corcept’s growth was predicated on new indications for relacorilant (a next-generation cortisol modulator). The FDA’s rejection of relacorilant in Cushing’s syndrome (hypercortisolism) is a major setback – it delays potential approval by perhaps several years (if new trials are needed) (www.biospace.com). This not only stalls revenue diversification but may allow competitors to catch up. Any clinical trial failure or further regulatory hurdles (e.g. an unexpectedly negative FDA decision on another application) would compound the difficulty. Beyond Cushing’s, Corcept is seeking approval of relacorilant combined with chemotherapy for platinum-resistant ovarian cancer – an NDA is under FDA review with a PDUFA target of July 11, 2026 (www.biospace.com) (www.biospace.com). While Phase 3 data in ovarian cancer (the ROSELLA study) were positive (www.biospace.com) (www.biospace.com), approval is not guaranteed, and even if approved, uptake in oncology could be gradual. Pipeline concentration is a risk: Corcept’s pipeline (relacorilant in various uses, plus earlier-stage candidates like dazucorilant) all revolve around cortisol modulation. A scientific or safety issue with this mechanism could therefore undermine multiple programs. Additionally, clinical development is inherently uncertain – as Corcept’s own filings note, “failure can occur at any time” in drug development (www.sec.gov). Investors should be wary that future trials might not succeed or might reveal safety concerns, especially as the company expands into oncology and metabolic disease indications that come with different challenges.
Legal and Regulatory Overhang: The wave of shareholder lawsuits is another red flag. While securities class actions are common after big stock drops, they suggest potential weaknesses in management’s communication or execution. The current suits allege that Corcept misrepresented trial results and prospects of relacorilant (ir.corcept.com) (www.biospace.com) – essentially accusing management of overpromising. Regardless of the outcome (which could take years), these suits will consume management attention and may lead to legal costs or settlement expenses (though insurance often covers a portion). Separately, Corcept is embroiled in an antitrust lawsuit filed by Teva, accusing Corcept of improper tactics to delay Korlym generics (such as patent misuse or exclusive dealing with suppliers) (www.law360.com) (www.law360.com). Parts of this case have survived motions to dismiss, indicating potential merit (www.law360.com). If Corcept were found liable for anti-competitive behavior, it could face damages or be forced to change its business practices. These legal battles highlight governance and compliance risks. They also underscore a pattern: Corcept has fiercely defended its franchise (which is understandable) but may have operated in gray areas that attract litigation. The recent Mifepristone controversy in the U.S. (over abortion pill access) adds another peripheral risk – although Korlym is used for Cushing’s, it is the same active ingredient (mifepristone), so any political or regulatory actions to restrict mifepristone could inadvertently impact Korlym’s availability or public perception (www.sec.gov). Finally, pricing pressure from regulators is a risk: the Inflation Reduction Act and other measures could target high-priced drugs like Korlym for Medicare price negotiation, which Corcept itself flagged as a concern (www.sec.gov). In sum, Corcept faces a gauntlet of risks – generic competition, pipeline uncertainty, legal challenges, and regulatory headwinds – that could significantly impact its financial performance and valuation.
Outlook and Open Questions
Despite the dark clouds, Corcept’s management remains outwardly optimistic. The company issued 2026 revenue guidance of $900–$1,000 million (www.biospace.com), roughly flat to up from 2025’s $761 million, implying they expect to offset generic erosion with new patient growth or new product contributions. This guidance strikes some analysts as ambitious – can Corcept realistically hit a ~$1 billion revenue run-rate in 2026 given likely Korlym price discounts and share loss? Investors should watch early 2026 sales trends (CORT’s quarterly results) to gauge how quickly generics are biting. If Korlym sales start declining, Corcept may need to revise guidance or accelerate its mitigation strategies (e.g. converting more patients to its authorized generic or pushing any new products).
Relacorilant’s Path Forward: A critical open question is what becomes of relacorilant for Cushing’s. Corcept is “engaged with the FDA” to find a path forward and still expresses confidence that ultimate approval will happen (www.biospace.com) (www.biospace.com). Will the FDA accept some alternative analysis or a limited label, or will a full new trial be required? The time and cost to re-approve relacorilant could be substantial if a new Phase 3 trial (or trials) must be run – potentially delaying approval by 2–3 years. Clarity on this will be crucial for modeling Corcept’s future. In the meantime, the ovarian cancer indication for relacorilant is the next catalyst. A FDA decision is due by mid-2026, and success there could provide Corcept a second product and revenue stream (albeit in a niche cancer population). How large that opportunity is – and how quickly oncologists adopt relacorilant if approved – remains to be seen. European approval for ovarian cancer is also expected by late 2026 (www.biospace.com), which could open another market.
Managing the Transition: Corcept’s strategy to navigate the loss of Korlym exclusivity is an open question. With over $0.5 billion in cash, will the company invest in acquisitions or partnerships to diversify its portfolio? Thus far, Corcept’s pipeline is internally developed, but the current situation might prompt looking at in-licensing new assets to bolster growth. Another question is whether Corcept will adjust its capital return policy – for instance, slowing or suspending share buybacks to conserve cash until the outlook stabilizes. The company has historically been very cash-generative, but that could change rapidly post-generic entry. Investors will want to see prudent cash management in this uncertain period.
Resolution of Legal Matters: Outcomes of the class-action suits and the Teva antitrust case are long-term questions. While such legal matters often settle, there’s uncertainty around potential financial impacts or required changes in corporate practices. A key point for shareholders is whether these disputes could distract management or constrain strategic options (e.g. if tied up in court). On the flip side, if relacorilant eventually secures FDA approval (for Cushing’s or ovarian cancer) and Korlym generics stabilize (for example, if Corcept’s authorized generic retains substantial share), Corcept could emerge from this period with a broader product base and restored growth. However, the gap between Korlym and relacorilant revenue – both timing and magnitude – is an open question. Some analysts see a “massive expectation gap” in Corcept’s story post-patent loss (www.ainvest.com) – the company’s own guidance and optimism may not fully account for the challenges ahead.
In summary, Corcept Therapeutics is at a crossroads. The next 12–18 months will answer several critical questions: Can the company successfully pivot its Cushing’s franchise to relacorilant or other therapies? Will the ovarian cancer indication validate relacorilant’s value? How steep will the Korlym decline be with multiple generics in play? And can management rebuild trust with investors amid litigation and past communication missteps? The company’s cash cushion and past profitability give it some breathing room to execute a turnaround. But given the confluence of a drug approval failure, impending revenue cliff, and legal scrutiny, Corcept faces significant challenges. Investors should remain alert to further updates – positive or negative – as the story evolves, including any guidance revisions, FDA meeting outcomes, or settlement of lawsuits. This “CORT alert” underscores both the downside risks that have materialized and the pivotal events on the horizon that will shape Corcept’s future.
Sources: Corcept SEC 10-K and filings (www.sec.gov) (www.sec.gov); Corcept press releases and Business Wire (www.biospace.com) (www.biospace.com); FDA and industry news via BioSpace (www.biospace.com) (www.biospace.com); Bloomberg Law (news.bloomberglaw.com); Investor class action notices (ir.corcept.com); Nasdaq/Zacks analyst commentary (www.nasdaq.com); and other cited references.
For informational purposes only; not investment advice.